Dystrophic Epidermolysis Bullosa Treatment Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast – 2022 to 2028

The Global Dystrophic Epidermolysis Bullosa Treatment Market was valued over US$ 412 Mn in 2020 and is projected to expand at a CAGR of 5% during the forecast period 2022 to 2028.

Dystrophic epidermolysis bullosa (DEB) is the second most common form of epidermolysis bullosa. Epidermolysis bullosa is a rare condition that belongs to a group of diseases that cause blistering and weakening of the skin. Blisters may occur in response to heat, scratches, rubs, or minor injuries from adhesive tape. In the most severe cases, blisters develop inside the body, such as in the stomach or in the mouth. In most cases, epidermolysis bullosa is hereditary and usually occurs in childhood. There are two types of bullous epidermolysis. One is autosomal dominant dystrophic bullous blisters (DDEB) and autosomal recessive bullous bullae (RDEB). In recent years, the number of patients with epidermolysis bullosa, one of the factors expected to drive the treatment market for epidermolysis bullosa, has increased significantly.

Market Segments

By Treatment

• Antibiotics
• Corticosteroids
• Anticonvulsants
• Opioid Analgesics

By Disease Type

• Dominant Dystrophic Epidermolysis Bullosa (DDEB)
• Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Key Players

• Krystal Biotech
• Castle Creek Biosciences, Inc.
• Abeona Therapeutics, Inc.
• Amryt Pharma plc
• Wings Therapeutics
• Phoenix Tissue Repair
• InMed Pharmaceuticals, Inc.
• RegeneRx
• Holostem Terapie Avanzate S.r.l.

Scope of the Report

The research study analyzes the global Dystrophic Epidermolysis Bullosa Treatment industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:

Recent Developments

o Market Overview and growth analysis
o Import and Export Overview
o Volume Analysis
o Current Market Trends and Future Outlook
o Market Opportunistic and Attractive Investment Segment

Geographic Coverage

o North America Market Size and/or Volume
o Latin America Market Size and/or Volume
o Europe Market Size and/or Volume
o Asia-Pacific Market Size and/or Volume
o Rest of the world Market Size and/or Volume

Key Questions Answered by Dystrophic Epidermolysis Bullosa Treatment Market Report

1. What was the Dystrophic Epidermolysis Bullosa Treatment Market size in 2020 and 2021; what are the estimated growth trends and market forecast (2022-2028).

2. What will be the CAGR of Dystrophic Epidermolysis Bullosa Treatment Market during the forecast period (2022-2028)?
3. Which segments (product type/applications/end-user) were most attractive for investments in 2022? How these segments are expected to grow during the forecast period (2022-2028).
4. Which manufacturer/vendor/players in the Dystrophic Epidermolysis Bullosa Treatment Market was the market leader in 2020?
5. Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.